View Item 

Show simple item record

Molecular characterization reveals NF1 deletions and FGFR1‐activating mutations in a pediatric spinal oligodendroglioma

dc.contributor.authorBruzek, Amy K.
dc.contributor.authorZureick, Andrew H.
dc.contributor.authorMcKeever, Paul E.
dc.contributor.authorGarton, Hugh J. L.
dc.contributor.authorRobertson, Patricia L.
dc.contributor.authorMody, Rajen
dc.contributor.authorKoschmann, Carl J.
dc.date.accessioned2017-05-10T17:49:14Z
dc.date.available2018-08-07T15:51:22Zen
dc.date.issued2017-06
dc.identifier.citationBruzek, Amy K.; Zureick, Andrew H.; McKeever, Paul E.; Garton, Hugh J. L.; Robertson, Patricia L.; Mody, Rajen; Koschmann, Carl J. (2017). "Molecular characterization reveals NF1 deletions and FGFR1‐activating mutations in a pediatric spinal oligodendroglioma." Pediatric Blood & Cancer 64(6): n/a-n/a.
dc.identifier.issn1545-5009
dc.identifier.issn1545-5017
dc.identifier.urihttps://hdl.handle.net/2027.42/136755
dc.description.abstractPediatric spinal oligodendrogliomas are rare and aggressive tumors. They do not share the same molecular features of adult oligodendroglioma, and no previous reports have examined the molecular features of pediatric spinal oligodendroglioma. We present the case of a child with a recurrent spinal anaplastic oligodendroglioma. We performed whole exome (paired tumor and germline DNA) and transcriptome (tumor RNA) sequencing, which revealed somatic mutations in NF1 and FGFR1. These data allowed us to explore potential personalized therapies for this patient and expose molecular drivers that may be involved in similar cases.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherspinal cord neoplasms
dc.subject.otheranaplastic oligodendroglioma
dc.subject.otherfibroblast growth factor receptor type 1
dc.subject.othermolecular sequence data
dc.subject.otherNF1
dc.subject.otherprecision medicine
dc.titleMolecular characterization reveals NF1 deletions and FGFR1‐activating mutations in a pediatric spinal oligodendroglioma
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136755/1/pbc26346_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136755/2/pbc26346.pdf
dc.identifier.doi10.1002/pbc.26346
dc.identifier.sourcePediatric Blood & Cancer
dc.identifier.citedreferenceKreiger PA, Okada Y, Simon S, et al. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol. 2005; 109: 387 – 392.
dc.identifier.citedreferenceSimonetti G, Gaviani P, Botturi A, et al. Clinical management of grade III oligodendroglioma. Cancer Manag Res. 2015; 7: 213 – 223.
dc.identifier.citedreferenceStrickland BA, Cachia D, Jalali A, et al. Spinal anaplastic oligodendroglioma with oligodendrogliomatosis: Molecular markers and management: Case report. Neurosurgery. 2016; 78: E466 – E473.
dc.identifier.citedreferenceDemlova R, Melicharkova K, Rehak Z, et al. Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. Curr Oncol. 2014; 21: e790 – e793.
dc.identifier.citedreferenceLundar T, Due‐Tønnessen BJ, Egge A, et al. Neurosurgical treatment of oligodendroglial tumors in children and adolescents: A single‐institution series of 35 consecutive patients. J Neurosurg Pediatr. 2013; 12: 241 – 246.
dc.identifier.citedreferenceMerchant TE, Nguyen D, Thompson SJ, et al. High‐grade pediatric spinal cord tumors. Pediatr Neurosurg. 1999; 30: 1 – 5.
dc.identifier.citedreferenceWang F, Qiao G, Lou X. Spinal cord anaplastic oligodendroglioma with 1p deletion: Report of a relapsing case treated with temozolomide. J Neurooncol. 2011; 104: 387 – 394.
dc.identifier.citedreferencevan den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long‐term follow‐up of EORTC brain tumor group study 26951. J Clin Oncol. 2013; 31: 344 – 350.
dc.identifier.citedreferenceWesseling P, van den Bent M, Perry A. Oligodendroglioma: Pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129: 809 – 827.
dc.identifier.citedreferenceMody RJ, Wu YM, Lonigro RJ, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. J Am Med Assoc. 2015; 314: 913 – 925.
dc.identifier.citedreferenceChi AS, Batchelor TT, Yang D, et al. BRAF V600E mutation identifies a subset of low‐grade diffusely infiltrating gliomas in adults. J Clin Oncol. 2013; 31: e233 – e236.
dc.identifier.citedreferenceCohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high‐grade gliomas in children: A report from the Children’s Oncology Group. Neuro‐oncology. 2011; 13: 317 – 323.
dc.identifier.citedreferenceHyder DJ, Sung L, Pollack IF, et al. Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: Results from the CCG 945 experience. J Neurooncol. 2007; 83: 1 – 8.
dc.identifier.citedreferenceMacDonald TJ, Aguilera D, Kramm CM. Treatment of high‐grade glioma in children and adolescents. Neuro‐oncology. 2011; 13: 1049 – 1058.
dc.identifier.citedreferenceLin AL, Gutmann DH. Advances in the treatment of neurofibromatosis‐associated tumours. Nat Rev Clin Oncol. 2013; 10: 616 – 624.
dc.identifier.citedreferenceRatner N, Miller SJ. A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015; 15: 290 – 301.
dc.identifier.citedreferenceGao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6: l1.
dc.identifier.citedreferenceYagi T, Ohata K, Haque M, Hakuba A. Intramedullary spinal cord tumour associated with neurofibromatosis type 1. Acta Neurochir. 1997; 139: 1055 – 1060.
dc.identifier.citedreferenceHallinan N, Finn S, Cuffe S, et al. Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat Rev. 2016; 46: 51 – 62.
dc.identifier.citedreferenceAmeratunga M, McArthur G, Gan H, et al. Prolonged disease control with MEK inhibitor in neurofibromatosis type I‐associated glioblastoma. J Clin Pharm Ther. 2016; 41: 357 – 359.
dc.identifier.citedreferenceNickel RS, Daves M, Keller F. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib. Pediatr Blood Cancer. 2015; 62: 2050 – 2051.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pbc26346_am.pdf
Size:
865.7KB
Format:
PDF
View/Open
Name:
pbc26346.pdf
Size:
371.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.